EU/3/16/1703: Orphan designation for the treatment of pro-opiomelanocortin deficiency
Table of contents
Setmelanotide has been authorised in the EU as Imcivree since 16 July 2021.
On 14 July 2016, orphan designation (EU/3/16/1703) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for setmelanotide for the treatment of pro-opiomelanocortin deficiency.
Treatment of pro-opiomelanocortin deficiency
|Orphan designation status||
|EU designation number||
|Date of designation||
Rhythm Pharmaceuticals Netherlands B.V.
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Imcivree at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the orphan medicine assessment report.
|July 2022||The sponsor's address was updated.|
|October 2021||The sponsorship was transferred to Rhythm Pharmaceuticals Netherlands B.V. in October 2021.|
|November 2020||The sponsorship was transferred to Rhythm Pharmaceuticals Limited, Ireland, in November 2020.|
|March 2019||The sponsorship was transferred to TMC Pharma (EU) Limited, Ireland, in March 2019.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: